About Genexine
Genexine is a company based in Seongnam-si (South Korea) founded in 2002 by Young Chul Sung.. The company has 89 employees as of December 31, 2024. Genexine has completed 1 acquisition, including Argos Therapeutics. Genexine operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Seongnam-si, South Korea
- Employees 89 as on 31 Dec, 2024
- Founders Young Chul Sung
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Genexine, Inc.
-
Annual Revenue
$1.99 M (USD)-33.75as on Dec 31, 2024
-
Net Profit
$-43.2 M (USD)4.74as on Dec 31, 2024
-
EBITDA
$-21.55 M (USD)13.87as on Dec 31, 2024
-
Latest Funding Round
$233 M (USD), Post-IPO
Mar 21, 2018
-
Investors
-
Employee Count
89
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Genexine
Genexine is a publicly listed company on the KRX with ticker symbol 095700 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Genexine
- Total Funding Total Funding
- Total Rounds 1
- Last Round Post-IPO — $233.0M
-
First Round
First Round
(21 Mar 2018)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2018 | Amount | Post-IPO - Genexine | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Genexine
Genexine has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Argos Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
An online gambling platform is operated for Tai Xiu games.
|
1997 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Genexine
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Genexine Comparisons
Competitors of Genexine
Genexine operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Genexine
Frequently Asked Questions about Genexine
When was Genexine founded?
Genexine was founded in 2002 and raised its 1st funding round 16 years after it was founded.
Where is Genexine located?
Genexine is headquartered in Seongnam-si, South Korea. It is registered at Seongnam-si, Gyeonggi-do, South Korea.
Who is the current CEO of Genexine?
Neil Warma is the current CEO of Genexine.
How many employees does Genexine have?
As of Dec 31, 2024, the latest employee count at Genexine is 89.
What is the annual revenue of Genexine?
Annual revenue of Genexine is $1.99M as on Dec 31, 2024.
What does Genexine do?
Genexine was founded in 2002 in Seongnam-si, South Korea. Focus is placed on developing immunotherapeutics targeting orphan diseases, cancers, and autoimmune disorders within the biotechnology sector. Drug candidates for growth hormone deficiencies, cervical cancers, and anemias have been advanced. The technology platform relies on Fc fusion proteins and DNA vaccines for these operations.
Who are the top competitors of Genexine?
Genexine's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Is Genexine publicly traded?
Yes, Genexine is publicly traded on KRX under the ticker symbol 095700.
How many acquisitions has Genexine made?
Genexine has made 1 acquisition, including Argos Therapeutics.
What is Genexine's ticker symbol?
The ticker symbol of Genexine is 095700 on KRX.